Arthritis research & therapy
-
Arthritis Res. Ther. · Nov 2015
Randomized Controlled Trial Multicenter StudyEffects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. ⋯ Tofacitinib monotherapy in DMARD-IR patients resulted in statistically significant and clinically meaningful improvements in multiple PROs versus placebo at month 3, with sustained improvements over 6 months.